世延生醫自主開發的口腔癌體外檢測試劑，在台灣時間2025年05月22日獲得香港特別行政區政府 衛生署醫療器械科(Medical device Division, Department of Health, Government of the Hong Kong Special Administrative region)醫療器材上市許可。
這是繼新加坡、澳洲取證後的再度攻克，象徵世延生醫在進軍東南亞市場再邁進一步，之後將更著重東南亞地區與亞太地區的市場佈局。
S&T Biomed CO., LTD.’s independently developed oral cancer in vitro diagnostic reagent obtained medical device market approval from the Medical Device Division, Department of Health, Government of the Hong Kong Special Administrative Region, on May 22, 2025 (Taiwan Time).
This marks another milestone following certifications in Singapore and Australia, symbolizing S&T Biomed CO., LTD.’s further progress in penetrating the Southeast Asian market. Moving forward, the company will place greater emphasis on market expansion in the Southeast Asia and Asia-Pacific regions.
